XPD Lys751Gln and Asp312Asn polymorphisms and hepatocellular carcinoma susceptibility: A meta-analysis of 11 case-control studies in an Asian population

  • Authors:
    • Qi Yang
    • Yan‑Fei Wei
    • Yuan Zhang
    • Guang‑Mei Huang
  • View Affiliations

  • Published online on: April 14, 2015     https://doi.org/10.3892/etm.2015.2421
  • Pages: 2406-2414
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

This meta-analysis was performed to evaluate the association between xeroderma pigmentosum complementary group D (XPD) Lys751Gln and Asp312Asn polymorphisms and susceptibility to hepatocellular carcinoma (HCC). PubMed, Embase, Google Scholar and the Chinese National Knowledge Infrastructure and the Chinese Biomedicine databases were systematically searched to identify relevant studies published up to June 1, 2014. Statistical analyses were performed using Stata version 12.0 software. A total of 11 case‑control studies, comprising 2,852 cases and 2,936 controls, were included. The results of the meta‑analysis revealed that a significant association between the risk of HCC and variant genotypes of the XPD Lys751Gln and Asp312Asn polymorphisms was evident in the homozygote comparison [Gln/Gln versus Lys/Lys: Odds ratio (OR), 1.831; 95% confidence interval (CI), 1.001‑3.349], heterozygote comparison (Lys/Gln versus Lys/Lys: OR, 1.486; 95% CI, 1.044‑2.114), dominant model (Gln/Gln + Lys/Gln versus Lys/Lys: OR, 1.540; 95% CI, 1.054‑2.249) and allelic contrast (Gln‑allele versus Lys‑allele: OR, 1.453; 95% CI, 1.032‑2.046) for the Lys751Gln polymorphism and the homozygote comparison for the Asp312Asn polymorphism (Asn/Asn versus Asp/Asp: OR, 1.352; 95% CI, 1.010‑1.808). By contrast, no significant association was observed in the recessive model for the Lys751Gln polymorphism (Gln/Gln versus Lys/Gln + Lys/Lys: OR, 1.603; 95% CI, 0.924‑2.779), or for the heterozygote comparison (Asn/Asp versus Asp/Asp: OR, 1.229; 95% CI, 0.857‑1.762), dominant model (Asn/Asn + Asp/Asn versus Asp/Asp: OR, 1.249; 95% CI, 0.910‑1.715), recessive model (Asn/Asn versus Asp/Asn + Asp/Asp: OR, 1.250; 95% CI, 0.940‑1.663) or allelic contrast (Asn‑allele versus Asp‑allele: OR, 1.226; 95% CI, 0.965‑1.557) for the Asp312Asn polymorphism. The present meta‑analysis has indicated that the XPD Lys751Gln polymorphism could be a potential biomarker of HCC susceptibility and that the XPD Lys751Gln and Asp312Asn polymorphisms could be risk factors for HCC susceptibility in an Asian population; however, further large‑scale and well-designed studies are required to reach a more precise and comprehensive conclusion.
View Figures
View References

Related Articles

Journal Cover

June-2015
Volume 9 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yang Q, Wei YF, Zhang Y and Huang GM: XPD Lys751Gln and Asp312Asn polymorphisms and hepatocellular carcinoma susceptibility: A meta-analysis of 11 case-control studies in an Asian population. Exp Ther Med 9: 2406-2414, 2015
APA
Yang, Q., Wei, Y., Zhang, Y., & Huang, G. (2015). XPD Lys751Gln and Asp312Asn polymorphisms and hepatocellular carcinoma susceptibility: A meta-analysis of 11 case-control studies in an Asian population. Experimental and Therapeutic Medicine, 9, 2406-2414. https://doi.org/10.3892/etm.2015.2421
MLA
Yang, Q., Wei, Y., Zhang, Y., Huang, G."XPD Lys751Gln and Asp312Asn polymorphisms and hepatocellular carcinoma susceptibility: A meta-analysis of 11 case-control studies in an Asian population". Experimental and Therapeutic Medicine 9.6 (2015): 2406-2414.
Chicago
Yang, Q., Wei, Y., Zhang, Y., Huang, G."XPD Lys751Gln and Asp312Asn polymorphisms and hepatocellular carcinoma susceptibility: A meta-analysis of 11 case-control studies in an Asian population". Experimental and Therapeutic Medicine 9, no. 6 (2015): 2406-2414. https://doi.org/10.3892/etm.2015.2421